💊 Arzneimittel A-Z 🧬 Targets 🛠 Werkzeuge 📚 Leitfäden
Alle Arzneimittel Arzneimittelklassen Therapeutische Bereiche Nebenwirkungen
Leitfäden Glossar Zeitleiste
Vergleiche Arzneimittelreisen Arzneimittel-Wirkstoffgruppen
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Avelumab

CHEMBL3833373 Phase 4 Zugelassen Antibody
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

A PD-L1 checkpoint inhibitor that blocks PD-L1 expressed on tumor cells from binding to PD-1 on T cells, unleashing an immune attack against the cancer. It is approved for Merkel cell carcinoma and urothelial carcinoma.

Therapeutische Bereiche

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Non-Small Cell Lung Cancer Rheumatoid Arthritis Melanoma Oncology Lymphoma Breast Cancer Prostate Cancer Colorectal Cancer Leukemia

Wirkmechanismus

Blocks immune checkpoint proteins (PD-1, PD-L1, or CTLA-4) that normally suppress T-cell activation, thereby releasing the brakes on the anti-tumor immune response. This allows cytotoxic T lymphocytes to recognize and destroy cancer cells.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Blocks immune checkpoint proteins (PD-1, PD-L1, or CTLA-4) that normally suppress T-cell activation, thereby releasing the brakes on the anti-tumor immune response. This allows cytotoxic T lymphocytes to recognize and …

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A PD-L1 checkpoint inhibitor that blocks PD-L1 expressed on tumor cells from binding to PD-1 on T cells, unleashing an immune attack against the cancer. It is approved for Merkel cell carcinoma and urothelial carcinoma.

Blocks immune checkpoint proteins (PD-1, PD-L1, or CTLA-4) that normally suppress T-cell activation, thereby releasing the brakes on the anti-tumor immune response. This allows cytotoxic T lymphocytes to recognize and destroy cancer cells.

Yes, Avelumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3833373. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.